Vivani Medical

Vivani Medical develops miniaturized, long-term drug implants using its proprietary NanoPortal platform. Its lead programs NPM-115 and NPM-119 are six-month GLP-1 implants for chronic weight management and type two diabetes, respectively. The company is advancing preclinical development of NPM-115 and aims to file an IND application in the second half of 2024. Vivani is also developing NPM-139, a potential once-yearly GLP-1 implant for chronic weight management. The company has licensed its exenatide delivery system to Okava Pharmaceuticals for veterinary applications.